PURPLE BIOTECH LTD. (PPBT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PPBT currently has 1.82B outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 322.37% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 20, 2026 |
F-3 filing: This filing includes a shelf registration for various securities up to USD 200,000,000 and a specific at-the-market offering for American Depositary Shares up to USD 824,331. |
1.8B | 0 |
| Aug 29, 2025 |
F-1 filing: Purple Biotech Ltd. is offering American Depositary Shares, Series B warrants, Pre-Funded warrants and Placement Agent Warrants on a "reasonable best efforts" basis. The ADSs and Warrants will be sold in a fixed combination. |
610M | 0 |
| Mar 10, 2025 |
20-F filing | 517.1M shares outstanding |
520M | 0 |
| Jul 22, 2024 |
F-1 filing: This F-1 filing details the resale of American Depositary Shares (ADS) representing ordinary shares, issued or issuable upon the exercise of warrants, by selling shareholders; the company will not receive any proceeds from the sale of the ADSs. |
250M | 0 |
| Mar 28, 2024 |
POS AM filing: This POS AM filing relates to the offering of ADSs representing Ordinary Shares by selling shareholders. The company will not receive any proceeds from the sale of these ADSs unless warrants are exercised for cash, which will be used for oncology drug development, asset acquisition, and working capital. |
250M | 0 |
| Mar 05, 2024 |
20-F filing | 252.4M shares outstanding |
250M | 0 |
| Oct 30, 2023 |
F-1 filing: This F-1 filing relates to the resale of 4,652,175 American Depositary Shares representing 46,521,750 Ordinary Shares by selling shareholders, issued or issuable upon the exercise of warrants. |
210M | 0 |
| Mar 23, 2023 |
F-3 filing: This is an F-3 filing for Purple Biotech Ltd. where selling shareholders may offer up to 2,215,190 American Depositary Shares (ADS) representing 22,151,900 ordinary shares. The ADSs were issued to the selling shareholders in connection with the acquisition of Immunorizon Ltd. |
210M | 0 |
| Mar 03, 2023 |
20-F filing | 184.8M shares outstanding |
180M | 0 |
| Dec 08, 2022 |
F-3 filing: This F-3 filing from Purple Biotech Ltd. registers American Depositary Shares, ordinary shares, preferred shares, warrants, overallotment purchase rights, subscription rights, units and/or capital notes for potential sale, with an aggregate offering price of up to USD 200,000,000 and a ATM offering for up to USD 11,600,000 of American Depositary Shares through Jefferies LLC. |
180M | 0 |
| Mar 09, 2022 |
20-F filing | 178.0M shares outstanding |
180M | 0 |
| Mar 16, 2021 |
20-F filing | 17.2M shares outstanding |
17M | 69M |
| Jul 10, 2020 |
F-3 filing: This prospectus relates to the disposition from time to time of up to 28,048,613 American Depositary Shares, each representing 1 ordinary share. |
20M | 66M |
| Jul 10, 2020 |
POS AM filing: This is a POS AM filing for Kitov Pharma, relating to the disposition of American Depositary Shares and warrants. |
20M | 66M |
| May 13, 2020 |
F-3 filing: This F-3 filing is for the disposition of up to 38,358,944 American Depositary Shares, each representing 1 ordinary share, by selling shareholders. |
20M | 38M |
| Mar 23, 2020 |
20-F filing | 19.6M shares outstanding |
20M | 0 |